Hepatitis A and E: Update on prevention and epidemiology

Vaccine

Volumn 28, Issue 3, 2010, Pages 583-588

  FitzSimons, David ^a   Hendrickx, Greet ^b   Vorsters, Alex ^b   Van Damme, Pierre ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Viral Hepatitis Prevention Board   (Belgium)

Author keywords

Epidemiology; Hepatitis A; Hepatitis E; Prevention; Vaccines

Indexed keywords

CAPSID PROTEIN; HEPATITIS A VACCINE; HEPATITIS E VACCINE; PARACETAMOL;

CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FOOD CONTAMINATION; HEALTH CARE COST; HEPATITIS A; HEPATITIS E; HUMAN; INFECTION RISK; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; VIRUS TRANSMISSION;

HEPATITIS A; HEPATITIS E; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 71149121136     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.136     Document Type: Conference Paper

References (5)

1. ECDC Meeting Report. Technical meeting on hepatitis A outbreak response. Riga, November 2008. Stockholm: European Centre for Disease Prevention and Control; 2009.
2. Hepatitis A vaccines: WHO position paper. Weekly Epidemiological Record 2000;75(5):38-44.
3. Shrestha M.P., Scott R.M., Joshi D.M., Mammen Jr. M.P., Thapa G.B., Thapa N., et al. Safety and efficacy of a recombinant hepatitis E vaccine. New England Journal of Medicine 356 (2007) 895-903
4. Li S.W., Zhang J., Li Y.M., Ou S.H., Huang G.Y., He Z.Q., et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 23 22 (2005) 2893-2901
5. http://www.gavialliance.org/resources/3____Vaccine_Investment_Strategy.pdf (accessed 12 October 2009).